Prudential PLC Buys 5,507 Shares of IDEXX Laboratories, Inc. $IDXX

Posted by on Jun 5th, 2026

Prudential PLC grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 11.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,709 shares of the company’s stock after acquiring an additional 5,507 shares during the period. Prudential PLC owned 0.06% of IDEXX Laboratories worth $34,983,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.7%

IDEXX Laboratories stock opened at $564.74 on Friday. The stock has a 50-day simple moving average of $563.32 and a 200 day simple moving average of $632.63. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $44.55 billion, a P/E ratio of 41.59, a PEG ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on IDXX. Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

Check Out Our Latest Research Report on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Featured Articles

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.